NOVOLOG
NOVOLOG- insulin aspart injection, solution
A-S Medication Solutions
1 INDICATIONS AND USAGE
NOVOLOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
2 DOSAGE AND ADMINISTRATION
2.1 Important Administration Instructions
- •
- Always check insulin labels before administration [see Warnings and Precautions (5.4)].
- •
- Inspect NOVOLOG visually before use. It should appear clear and colorless. Do not use NOVOLOG if particulate matter or coloration is seen.
- •
- Use NOVOLOG FlexPen and NOVOLOG FlexTouch with caution in patients with visual impairment who may rely on audible clicks to dial their dose.
- •
- Use PenFill cartridges with caution in patients with visual impairment.
- •
- Do NOT mix NOVOLOG with other insulins when administering using a continuous subcutaneous infusion pump.
2.2 Route of Administration
Subcutaneous Injection
- •
- Inject NOVOLOG subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm.
- •
- Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (5.2) and Adverse Reactions (6.1, 6.3)].
- •
- During changes to a patient’s insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions (5.2)].
- •
- The NOVOLOG FlexPen and FlexTouch dial in 1-unit increments.
- •
- NOVOLOG administered by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting insulin.
- •
- NOVOLOG may be diluted with Insulin Diluting Medium for NOVOLOG for subcutaneous injection. Diluting one part NOVOLOG to nine parts diluent will yield a concentration one-tenth that of NOVOLOG (equivalent to U-10). Diluting one part NOVOLOG to one part diluent will yield a concentration one-half that of NOVOLOG (equivalent to U-50).
Continuous Subcutaneous Infusion (Insulin Pump)
- •
- Refer to the continuous subcutaneous insulin infusion pump user manual to see if NOVOLOG can be used with the insulin pump. Use NOVOLOG in accordance with the insulin pump system’s instructions for use.
- •
- Train patients using continuous subcutaneous insulin fusion pump therapy to administer insulin by injection and have alternate insulin therapy available in case of pump failure.
- •
- Administer NOVOLOG by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer. Rotate infusion sites within the same region to reduce the risk of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (5.2) and Adverse Reactions (6.1, 6.3)].
- •
- During changes to a patient’s insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions (5.2)].
- •
- Follow healthcare provider recommendations when setting basal and meal time infusion rate.
- •
- Change the NOVOLOG in the reservoir at least every 7 days or according to the pump user manual, whichever is shorter.
- •
- Change the infusion set and the infusion set insertion site according to the manufacturer’s user manual.
- •
- Do NOT dilute or mix NOVOLOG when administering by continuous subcutaneous infusion.
- •
- Do NOT expose NOVOLOG in the pump reservoir to temperatures greater than 98.6°F (37°C).
Intravenous Administration
- •
- Dilute NOVOLOG to concentrations from 0.05 unit/mL to 1 unit/mL insulin aspart in infusion systems using polypropylene infusion bags. NOVOLOG is stable in infusion fluids such as 0.9% Sodium Chloride Injection, USP.
- •
- Administer NOVOLOG intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia [see Warnings and Precautions (5.3, 5.6) and How Supplied/Storage and Handling (16.2)].
2.3 Dosage Information
- •
- Individualize and adjust the dosage of NOVOLOG based on route of administration, the individual’s metabolic needs, blood glucose monitoring results and glycemic control goal.
- •
- Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness [see Warnings and Precautions (5.2, 5.3) and Use in Specific Populations (8.6, 8.7)].
- •
- Dosage adjustment may be needed when switching from another insulin to NOVOLOG [see Warnings and Precautions (5.2)].
2.4 Dosage Adjustment Due to Drug Interactions
- •
- Dosage adjustment may be needed when NOVOLOG is co-administered with certain drugs [see Drug Interactions (7)].
2.5 Instructions for Mixing with Other Insulins
| NOVOLOG subcutaneous injection route |
• If NOVOLOG is mixed with NPH insulin, draw NOVOLOG into the syringe first and inject immediately after mixing. |
| NOVOLOG continuous subcutaneous infusion route (Insulin Pump) | Do NOT mix NOVOLOG with any other insulin. |
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.